A metastatic colon cancer model using nonoperative transanal rectal injection.
BACKGROUND
This study aimed to develop a noninvasive orthotopic model for metastasis of colon and rectal cancer using a transanal approach. Currently, the most accurate orthotopic representation of metastatic human colon cancer is via a cecal injection. The transanal model allows for further examination of systemic immune responses, tumor take, and onset of metastasis without prior surgical intervention.


METHODS
For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening. Murine colon cancer parental CT26 or luciferase-labeled CT26 (CT26-luc) cells were injected submucosally into the distal posterior rectum (30 CT26 and 30 CT26 injections) at concentrations of 2.5 x 10(4), 1 x 10(5), and 1 x 10(6) in a volume of 50 microl. Tumor growth and metastatic development was monitored at 5-day intervals for 50 days. All the remaining mice were killed on postinjection day 50.


RESULTS
The optimal concentration for metastasis and survival of the mice was 2.5 x 10(4) cells. Higher concentrations of cells yielded higher mortality but did not result in metastasis. The overall success of tumor growth in both experiments using the transanal rectal injection was 65%. Histology showed that all tumors were poorly differentiated adenocarcinomas. Two mice (3.3%) from the 2.5 x 10(4) CT26-luc group showed metastatic colonic adenocarcinoma to the liver on postinjection day 50.


CONCLUSIONS
Transanal rectal injection of colon cancer cells offers a nonoperative orthotopic murine model for colon cancer that may lead to the development of metastasis. By using an orthotopic model, more aspects of metastatic colon cancer can be evaluated without the influence of a previous abdominal incision. These results warrant more investigation.
Donigan
Melissa
M
Cancer Research Institute of MD Anderson Cancer Center Orlando, 110 Bonnie Loch Court, Orlando, FL 32806, USA.
Loh
Bryan D
BD
Norcross
Laurie S
LS
Li
Shuan
S
Williamson
Paul R
PR
DeJesus
Samuel
S
Ferrara
Andrea
A
Gallagher
Joseph T
JT
Baker
Cheryl H
CH
D001003:Anal Canal; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000556:secondary*; D004195:Disease Models, Animal; D007267:Injections / Q000379:methods; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation / Q000379:methods*; D012007:Rectum / Q000473:pathology*
Cancer Res. 1988 Apr 1;48(7):1943-8
3349467
Surg Oncol. 1992 Jun;1(3):251-6
1341258
Cancer Sci. 2004 Jun;95(6):514-9
15182433
N Engl J Med. 2004 May 13;350(20):2050-9
15141043
Lancet. 2002 Jun 29;359(9325):2224-9
12103285
Am J Pathol. 2007 Mar;170(3):1077-85
17322390
Surg Endosc. 2003 Jun;17(6):972-8
12640542
Eur J Surg Oncol. 2008 Apr;34(4):476-81
17698312
J Surg Res. 2009 Jun 15;154(2):299-303
19101690
Cancer Res. 1975 Sep;35(9):2434-9
1149045
Arch Surg. 1995 Jun;130(6):649-53
7763175
Surg Endosc. 1998 Aug;12(8):1092-5
9685551
Dig Surg. 2005;22(1-2):16-25
15838167
Clin Cancer Res. 2000 Jun;6(6):2556-61
10873112
Int J Oncol. 2005 Jul;27(1):113-20
15942650
Int J Cancer. 1989 Jul 15;44(1):177-81
2744889